The OTUD3 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population of Raji cells engineered for targeted disruption of the OTUD3 gene. This gene-edited pool offers a heterogeneous knockout model, providing a practical and robust tool for functional studies without the need for monoclonal isolation. The polyclonal format preserves a range of OTUD3-deficient genotypes, allowing efficient loss-of-function analysis in a B lymphocyte background.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive human B lymphocyte cell line established from a Burkitt lymphoma patient. As a well-characterized model in immunological and oncological research, Raji cells recapitulate features of aggressive B-cell malignancies, including constitutive NF-??B activation and lymphoblastoid growth. They are extensively utilized to explore mechanisms of B-cell transformation, immune surveillance, and antibody production, offering a disease-relevant cellular environment for studying signaling pathways implicated in lymphoma.
OTUD3 encodes a deubiquitinase that selectively hydrolyzes K6- and K11-linked polyubiquitin chains, acting as a critical suppressor of the PTEN/AKT and NF-??B signaling axes. Mechanistically, OTUD3 directly interacts with and deubiquitinates PTEN, preventing its proteasomal turnover and thereby maintaining sustained inhibition of AKT phosphorylation and downstream prosurvival signals. Concurrently, OTUD3 stabilizes TRAF3 through deubiquitination, which reinforces TRAF3-mediated suppression of NF-??B transcriptional programs. These dual regulatory mechanisms position OTUD3 as a pivotal modulator of apoptosis, cell proliferation, and inflammatory responses.
Within the Raji lymphoma model, where AKT and NF-??B pathways are frequently hyperactive, OTUD3 deficiency is anticipated to amplify these oncogenic cascades, potentially leading to enhanced survival and reduced apoptosis. This polyclonal knockout resource enables systematic investigation of OTUD3’s tumor-suppressive functions in a B-cell context, permitting assessment of how OTUD3 loss influences PTEN stability, AKT activation, TRAF3 abundance, and NF-??B-driven transcription. Such studies may uncover mechanistic insights into B-cell lymphomagenesis and identify vulnerabilities in OTUD3-dysregulated malignancies.
Researchers can employ these cells in diverse experimental approaches, including quantitative Western blotting for PTEN and phosphorylated AKT, flow cytometric detection of apoptosis, NF-??B luciferase reporter assays, co-immunoprecipitation to confirm OTUD3?CPTEN and OTUD3?CTRAF3 interactions, and cell viability measurements. The polyclonal nature also facilitates screens for novel OTUD3-binding partners using proteomic strategies. Together, these applications support detailed functional dissection of OTUD3-mediated signaling and its relevance to B-cell lymphoma and inflammatory disorders. For additional information, please contact Ascent Research.
